Abstract
We translated these laboratory findings to a single-arm, phaseII clinical study in which patients with previously untreatedstage III/IV follicular lymphoma were initially treated intominimal residual disease (MRD) state with a uniformchemotherapy regimen, PACE (prednisone/doxorubicin/cyclophosphamide/etoposide), a modified ProMACE regimen(cyclophosphamide/etoposide/doxorubicin/mechlorethamine/procarbazine plus high-dose methotrexate with leucovorin rescueand prednisone) without methotrexate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
